| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d01f6469c1b1fbf6a49910d7d068ec4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1767 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2016-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df9d714462dd5f8cde9a4e464f8bdc0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1775413e69e443406ee59569e7ccd3dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f3f61e3c2ac473c9ff1477f81e26cd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec6ed50a8550aab0d3233cee71c18629
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79ec74e48a2d3bf995f88f536541866e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f11ebbc02f465dae307164165fff4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2742e4143cd3f43ab964ada23d7ccc06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ef9ab750df5c4c135950fe0325be0ef |
| publicationDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017095530-A1 |
| titleOfInvention |
Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels |
| abstract |
Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186. |
| priorityDate |
2011-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |